NeoGenomics (NYSE: NEO) — Perfil da empresa, notícias e dados financeiros
NeoGenomics is a lab specializing in genetic testing for cancer, offering extensive services across the U.S. to personalize treatment.
NeoGenomics
NeoGenomics (NASDAQ:NEO) is a specialized laboratory focused on genetic testing for cancer diagnosis, prognosis, and treatment planning. The company operates through a network of labs across the United States, offering a wide range of testing services, including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, molecular genetics, and next-generation sequencing. NeoGenomics aims to support personalizing cancer care through its comprehensive testing solutions, working closely with pathologists, oncologists, academic centers, and pharmaceutical companies. Their projects often involve developing new tests and technologies to stay at the forefront of precision medicine in oncology, with the objective of enhancing patient outcomes through tailored treatment approaches.
Resumo
Operações
Produtos e/ou serviços de NeoGenomics
- Comprehensive oncology testing services, offering a full suite of molecular diagnostic tests.
- Pharma Services, providing support for drug development and clinical trials.
- NeoTYPE Cancer Profiles, targeted sequencing panels for precise cancer diagnosis and treatment planning.
- MultiOmyx, a proprietary technology for high-definition immunohistochemistry analysis.
- Informatics services, utilizing data analytics for personalized treatment recommendations.
- Liquid biopsy tests, offering non-invasive cancer detection and monitoring solutions.
equipe executiva do NeoGenomics
- Anthony P. ZookCEO & Director
- Warren StonePresident & COO
- Elizabeth A. FloegelChief Digital & Information Officer
- Gary PassmanChief People & Culture Officer
- Abhishek JainExecutive VP & CFO
- Gregory D. AunanSenior VP & Chief Accounting Officer
- Andrew Frederick BrackmannVice President of Investor Relations
- Clarence CooperVice President of Compliance & Privacy
- Andrew A. LukowiakChief Innovation Officer
- Priya VedaramanSenior Vice President of Finance
Últimas notícias sobre a NeoGenomics
Histórico de dividendos
Dividendos por ação pagos pela NeoGenomics, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2020 | — | — | — | $0.4000 |
Principais indicadores financeiros
Resultados divulgados pela NeoGenomics, em USD.
- Cap. de mercado
- 2,2 bi
- Receita (TTM)
- 766,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -6.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 727,3 mi | -66,1 mi | -108 mi | |
| 660,6 mi | -92,1 mi | -78,7 mi | |
| 591,6 mi | -107,7 mi | -88 mi | |
| 509,7 mi | -157,6 mi | -144,3 mi |